Matthew Aldridge - Concepedia

Author

Matthew Aldridge

Also Known As

Aldridge, M, M Aldridge, M. Aldridge, M. D. Aldridge, M.D. Aldridge, Matthew Aldridge, Matthew D Aldridge, Matthew D. Aldridge

Publications

612

Citations

H-Index

Concepts

All Affiliations

University College London University College London Hospitals NHS Foundation Trust University College Hospital University of Oxford

About

Matthew Aldridge is an author at University College London specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	139
2	Health Sciences	2	2	115
3	Pharmacology	1	1	13
4	Radiation Medicine	1	1	11
5	Adaptive Radiotherapy	1	1	11

Matthew Aldridge

Publications

587

Citations

H-Index

Page 1

	Year	Citations
<sup>177</sup>Lu-DOTATATE Molecular Radiotherapy for Childhood Neuroblastoma J. Gains, Jamshed Bomanji, Naomi Fersht, Journal of Nuclear Medicine	2011	160
<sup>18</sup>F-FDG PET/CT and <sup>123</sup>I-Metaiodobenzylguanidine Imaging in High-Risk Neuroblastoma: Diagnostic Comparison and Survival Analysis Mark N. Gaze, Kevin P. Sullivan, Matthew Aldridge, Journal of Nuclear Medicine	2011	96
Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation Jillian Maclean, Matthew Aldridge, Jamshed Bomanji, Pituitary Pituitary GlandPreliminary EvaluationMedicineRadionuclide TherapyVariable Clinical Response	2013	69
68Ga-DOTATATE and 123I-mIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: implications for molecular radiotherapy J. Gains, Matthew Aldridge, Maria Vittoria Mattoli, Nuclear Medicine Communications	2020	48
A phase IIa trial of molecular radiotherapy with 177-lutetium DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma J. Gains, V. V. Moroz, Matthew Aldridge, European Journal of Nuclear Medicine and Molecular Imaging Radiation TherapyMolecular RadiotherapyMedicinePhase Iia TrialRadiopharmaceutical Therapy	2020	46
Evaluation of a low-dose/slow-rotating SPECT-CT system M. Hamann, Matthew Aldridge, John Dickson, Physics in Medicine and Biology	2008	39
Radiomics-Based Texture Analysis of 68Ga-DOTATATE Positron Emission Tomography and Computed Tomography Images as a Prognostic Biomarker in Adults With Neuroendocrine Cancers Treated With 177Lu-DOTATATE Charlotte Atkinson, Balaji Ganeshan, Raymond Endozo, Frontiers in Oncology	2021	36
Radiation exposure to comforters and carers during paediatric molecular radiotherapy J. Gains, Christopher Walker, T. M. Sullivan, Pediatric Blood & Cancer	2014	23
Clinical evaluation of reducing acquisition time on single-photon emission computed tomography image quality using proprietary resolution recovery software Matthew Aldridge, Wendy W. Waddington, John Dickson, Nuclear Medicine Communications	2013	23
SIDE-EFFECTS OF TRANYLCYPROMINE Matthew Aldridge, N. W. Oakley The Lancet Side-effects Of TranylcypromineAddictionMedicineToxicologyPharmacotherapy	1961	13

Page 1